Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

BACKGROUND AND PURPOSE: Risk factors for stroke are well-established in general populations but sparsely studied in individuals with impaired glucose tolerance. METHODS: We identified predictors of stroke among participants with impaired glucose tolerance in the Nateglinide and Valsartan in Impaire...

Full description

Bibliographic Details
Main Authors:	Preiss, D, Giles, T, Thomas, L, Sun, J, Haffner, S, Holman, R, Standl, E, Mazzone, T, Rutten, G, Tognoni, G, Chiang, F, McMurray, J, Califf, R
Format:	Journal article
Language:	English
Published:	2013

Similar Items

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
by: Preiss, D, et al.
Published: (2012)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
by: Califf, R, et al.
Published: (2008)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Latini, R, et al.
Published: (2013)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
by: Mcmurray, J, et al.
Published: (2011)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
by: Currie, G, et al.
Published: (2017)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
by: Krum, H, et al.
Published: (2010)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
by: Sharma, A, et al.
Published: (2016)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
by: Bethel, M, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
by: Bethel, M, et al.
Published: (2013)

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach
by: Theodorakis, M, et al.
Published: (2016)

Comparison of in vivo tests for glucose tolerance in subjects with normal, impaired glucose tolerance and type 2 diabetes
by: Hermans, M, et al.
Published: (1996)

Early detection of impaired glucose tolerance in young adults
by: May, Khin Soe, et al.
Published: (2013)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
by: Gerstein, H, et al.
Published: (2006)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
by: Califf, R, et al.
Published: (2003)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
by: Yates, T, et al.
Published: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
by: Yates, T, et al.
Published: (2014)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
by: Wamil, M, et al.
Published: (2020)

Expert Workshop on Impaired Glucose Tolerance Held in London, UK - 29 March 1995 - Introduction
by: Holman, R
Published: (1996)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
by: Shen, L, et al.
Published: (2012)

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study
by: Bales, C, et al.
Published: (2013)

The role of nicotinamide nucleotide transhydrogenase in insulin secretion and impaired glucose tolerance
by: Freeman, H, et al.
Published: (2005)

'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
by: Page, R, et al.
Published: (1993)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
by: Shen, L, et al.
Published: (2013)

Role of the transcription factor sox4 in insulin secretion and impaired glucose tolerance.
by: Goldsworthy, M, et al.
Published: (2008)

Prevalence of diabetes mellitus and impaired glucose tolerance in parents of women with gestational diabetes.
by: McLellan, J, et al.
Published: (1995)

GLUCOSE-TOLERANCE AND BETA-CELL FUNCTION ASSESSED BY CONTINUOUS INFUSION OF GLUCOSE AND ORAL GLUCOSE-TOLERANCE TEST
by: Levy, J, et al.
Published: (1992)

Hyperglycaemic progression in subjects with impaired glucose tolerance: association with decline in beta cell function.
by: Cook, J, et al.
Published: (1993)

Prevalence and pathophysiology of impaired glucose tolerance in three different high-risk white groups.
by: Page, R, et al.
Published: (1993)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
by: Dos Santos, M, et al.
Published: (2017)

Changes in forearm blood flow at elevated ambient temperature and their role in the apparent impairment of glucose tolerance.
by: Frayn, K, et al.
Published: (1989)

Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk.
by: Bowman, L, et al.
Published: (2002)

Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
by: Xu, S, et al.
Published: (2019)

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
Published: (2008)

Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance
by: Xu, S, et al.
Published: (2021)

Histological features of symptomatic carotid plaques in patients with impaired glucose tolerance and diabetes (oxford plaque study).
by: Redgrave, J, et al.
Published: (2008)

Evaluation of a self-administered oral glucose tolerance test
by: Bethel, M, et al.
Published: (2013)

Assessing the impact of blood sample type on the estimated prevalence of impaired glucose tolerance and diabetes mellitus in epidemiological surveys.
by: Farrer, M, et al.
Published: (1995)

Microbial-host co-metabolites are prodromal markers predicting phenotypic heterogeneity in behavior, obesity, and impaired glucose tolerance
by: Dumas, M, et al.
Published: (2017)

Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.
by: Farrer, M, et al.
Published: (1993)

Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
by: Mc Morrow, L, et al.
Published: (2018)